Could Geron Corporation Be a Millionaire-Maker Stock?


Its lead drug, imetelstat, has enjoyed all the ups and downs of clinical development. Promising results in late 2013 for oncology indications were followed by a full clinical hold from the U.S. Food and Drug Administration in early 2014 over liver toxicity concerns.



from Biotech News